RealTime Dynamix™: Multiple Sclerosis (US) Q3 2018 Spotlight

RealTime Dynamix™: Multiple Sclerosis (US) Q3 2018 Spotlight

Real time dynamix

Unaided awareness of Novartis’ siponimod increased compared to previous quarters, but neurologists appear split on how, or if, they will incorporate siponimod into their multiple sclerosis armamentarium, according to the latest wave of RealTime Dynamix: Multiple Sclerosis (US). View complimentary highlights from the Q3 wave of the report below.

Contact [email protected] for more information about the highlighted report or to see if your company already has access to the report series.

All company, brand or product names and logos in this document are trademarks of their respective holders.

2018-09-21T16:38:57+00:00